Press Releases

Date Title and Summary
Toggle Summary Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Data Presented at the 2019 Genitourinary Cancers Symposium Reinforces Benefits of Short Course of Treatment Using Stereotactic Body Radiation Therapy for Low- or Intermediate-Risk Prostate Cancer SUNNYVALE, Calif. , Feb. 22, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today
Toggle Summary Accuray And China Isotope And Radiation Corporation Enter Joint Venture Contract To Manufacture And Sell Radiation Oncology Systems In China
Joint Venture Uniquely Positioned to Serve World's Largest Growth Market for Radiation Oncology Systems Conference Call Today at 6:00 a.m. PT/ 9:00 a.m. ET SUNNYVALE, Calif. and TIANJIN, China , Jan. 28, 2019 /PRNewswire/ -- Accuray Asia Limited , a subsidiary of Accuray Incorporated (NASDAQ:
Toggle Summary Accuray Reports Fiscal 2019 Second Quarter Results
SUNNYVALE, Calif. , Jan. 22, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2019 ended December 31, 2018 . Fiscal Second Quarter Highlights Gross orders increased 29 percent year over year to a record $100.2 million 16
Toggle Summary The Urology Group Surpasses 1,600 Prostate Cancer Patients Treated with the Accuray CyberKnife® M6™ System
SUNNYVALE, Calif. , Jan. 17, 2019 /PRNewswire/ -- According to the American Cancer Society , prostate cancer is the most common cancer in American men other than skin cancer. Accuray Incorporated (NASDAQ: ARAY) and The Urology Group (TUG) are partnering to recognize TUG's commitment to improving
Toggle Summary Accuray To Report Fiscal 2019 Second Quarter Financial Results on January 22, 2019
SUNNYVALE, Calif., Jan. 8, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2018 on Tuesday, January 22, 2019 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m.
Toggle Summary Accuray to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
SUNNYVALE, Calif. , Jan. 2, 2019 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will present at the J.P. Morgan 37th Annual Healthcare Conference on Wednesday, January 9, 2019 at the Westin St. Francis Hotel in San Francisco .
Toggle Summary Accuray CyberKnife® System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade
Next-Generation Accuray Precision® Treatment Planning System With the CyberKnife VOLO™ Optimizer Also Reduces Treatment Planning Times Up to 90 Percent, Enabling Clinicians to Treat More Patients Each Day SUNNYVALE, Calif. , Dec. 6, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY)
Toggle Summary Accuray Appoints Shig Hamamatsu Chief Financial Officer
SUNNYVALE, Calif. , Nov. 19, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has named Shig Hamamatsu as senior vice president, chief financial officer effective immediately. Mr. Hamamatsu joined Accuray as its vice president of finance and
Toggle Summary Accuray Reports Fiscal 2019 First Quarter Financial Results
SUNNYVALE, Calif. , Oct. 30, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2019 ended September 30, 2018 . Company Highlights China Ministry of Health confirms Type A and B quota and licenses Gross orders increased 10
Toggle Summary Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
SUNNYVALE, Calif. , Oct. 17, 2018 /PRNewswire/ -- Building on its heritage of patient-first innovation, at this year's ASTRO ( American Society for Radiation Oncology ) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to